Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth

Following allegations from short seller Citron Research that it operates an illegal “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from China

More from Asia